Barinthus Biotherapeutics's total assets for Q3 2024 were $188.69M, an increase of 1.04% from the previous quarter. BRNS total liabilities were $29.23M for the fiscal quarter, a -2.44% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.